Ciltacabtagene Autoleucel (cilta-cel)
Carvykti
Near Add Your Location
Accepting patients
MonumenTAL-8
A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
- Bispecific Antibody
- CAR T Cell
- BCMA
- GPRC5D
- Phase 2
Accepting patients
CAR T Post Hematopoietic Cell Transplant
A Study to See if Anti-BCMA CAR T-Cell Therapy Can Be Made from People with Multiple Myeloma Who Have Had a Stem Cell Transplant
- CAR T Cell
- BCMA
- Phase 2
Accepting patients
CARTITUDE-6
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)
- Autologous Stem Cell Transplant
- CAR T Cell
- BCMA
- Phase 3
Accepting patients
aMMbition
A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination With Daratumumab SC (Tal-D) and Teclistamab SC in Combination With Daratumumab SC (Tec-D) Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
- Bispecific Antibody
- CAR T Cell
- BCMA
- GPRC5D
- Randomization
- Phase 2
Accepting patients
CAR-T for Patients with Renal Impairment
A Pilot Safety and Feasibility Study of Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
- CAR T Cell
- BCMA
- Phase 1
Accepting patients
Dasatinib & Quercetin with CAR-T Cell Therapy
DART: Phase II Study of Dasatinib and Quercetin in Patients With Relapsed, Refractory Multiple Myeloma Receiving CAR-T Therapy
- CAR T Cell
- Tyrosine Kinase (TK) Inhibitor
- Phase 2